Targeting of epidermal growth factor receptor in patients affected by biliary tract carcinoma [7]

Journal of Clinical Oncology

Volumn 25, Issue 9, 2007, Pages 1145-

  Leone, Francesco ^a   Pignochino, Ymera ^a   Cavalloni, Giuliana ^a   Aglietta, Massimo ^a  

^a CANDIOLO CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; K RAS PROTEIN; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

BILE DUCT CARCINOMA; CANCER GROWTH; CANCER INCIDENCE; DRUG RESPONSE; GENE AMPLIFICATION; GENE MUTATION; HUMAN; LETTER; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN TARGETING; TREATMENT OUTCOME; BILIARY TRACT TUMOR; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ANTAGONISM; METABOLISM; METHODOLOGY; NOTE; PATIENT SELECTION;

ANTINEOPLASTIC AGENTS; BILIARY TRACT NEOPLASMS; CLINICAL TRIALS; DISEASE-FREE SURVIVAL; HUMANS; PATIENT SELECTION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 34047211287     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.09.3427     Document Type: Letter

References (12)

1. Philip PA, Mahoney MR, Allmer C, et al: Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol 24:3069-3074, 2006
2. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004
3. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004
4. Pao W, Miller V, Zakowski M, et al: EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101:13306-13311, 2004
5. Cappuzzo F, Hirsch FR, Rossi E, et al: Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97:643-655, 2005
6. Pao W, Wang TY, Riely GJ, et al: KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2:e17, 2005 [E-Pub: February 22, 2005]
7. Shigematsu H, Lin L, Takahashi T, et al: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97:339-346, 2005
8. Soung YH, Lee JW, Kim SY, et al: Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas. Virchows Arch 446:483-488, 2005
9. Tannapfel A, Benicke M, Katalinic A, et al: Frequency of p16 (INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver Gut 47:721-727, 2000
10. Tada M, Omata M, Ohto M: High incidence of ras gene mutation in intrahepatic cholangiocarcinoma. Cancer 69:1115-1118, 1992
11. Itoi T, Takei K, Shinohara Y, et al: K-ras codon 12 and p53 mutations in biopsy specimens and bile from biliary tract cancers. Pathol Int 49:30-37, 1999
12. Leone F, Cavalloni G, Pignochino Y, et al: Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma. Clin Cancer Res 12:1680-1685, 2006